Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study

Clara Möser; Katsiaryna Prystupa; Martin Schön; Iryna Yurchenko; Kálmán B Bódis; Maximilian Huttasch; Filippo Michelotti; Yuliya Kupriyanova; Vera Schrauwen-Hinderling; Cesare Granata; Gidon J Bönhof; Alexander Strom; Christian Herder; Daniel Dörr; Sandra Trenkamp; Geronimo Heilmann; Pavel Bobrov; Klaus Straßburger; Julia Szendroedi; Mareike Cramer; Amin Polzin; Christian Jung; Malte Kelm; Volker Burkart; Robert Wagner; Michael Roden; Oana-Patricia Zaharia

doi:10.1186/s12933-026-03097-0

Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study

Clara Möser
, Katsiaryna Prystupa
, Martin Schön
, Iryna Yurchenko
, Kálmán B Bódis
, Maximilian Huttasch
, Filippo Michelotti
, Yuliya Kupriyanova
, Vera Schrauwen-Hinderling
, Cesare Granata
, Gidon J Bönhof
, Alexander Strom
, Christian Herder
, Daniel Dörr
, Sandra Trenkamp
, Geronimo Heilmann
, Pavel Bobrov
, Klaus Straßburger
, Julia Szendroedi
, Mareike Cramer

Amin Polzin, Christian Jung, Malte Kelm, Volker Burkart, Robert Wagner, Michael Roden, Oana-Patricia Zaharia

Research output: Contribution to journal › Article › Research › peer-review

Abstract

BACKGROUND: Humans with type 2 diabetes and/or metabolic dysfunction-associated steatotic liver disease (MASLD) are at higher risk of ST-segment elevation myocardial infarction (STEMI) and worse prognosis. However, mechanisms, prognostic factors and risk subtypes in humans with STEMI and (pre)diabetes with or without MASLD, are not fully understood.

METHODS: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) study is a prospective longitudinal cohort study, recruiting humans with different degrees of glucose tolerance after recent STEMI. This cohort study has the primary objective to detect changes in glycemia and insulin sensitivity derived from the oral glucose tolerance test (OGTT) and their relationships to cardiac function. Secondary objectives address tissue-specific insulin sensitivity and organ function, focusing on adipose tissue, liver and heart. Exploratory objectives comprise multiomic analyses and measures of mitochondrial function and quality of life. At 2 and 12 months after STEMI, participants undergo comprehensive cardiometabolic phenotyping (OGTT, modified Botnia clamp-test, magnetic resonance imaging/spectroscopy/elastography, high-resolution respirometry). Magnetic resonance-based techniques are employed to assess cardiovascular function and structure, adipose tissue distribution, skeletal muscle and hepatic lipid deposition and fibrosis, and hepatic energy metabolism. Exploratory analyses include multiomics of blood, urine, and stool samples. Multiomics analyses shall allow detecting biomarkers for stratification of cardiovascular disease risk. Currently, 100 participants have been included in DISTEMI, of whom 29% have type 2 diabetes.

CONCLUSION: The DISTEMI study integrates comprehensive cardiometabolic phenomic with multiomic profiling to identify cardiometabolic STEMI subtypes and predictors of outcomes, and to improve precision risk stratification and targeted prevention.

TRIAL REGISTRATION: NCT05046483.

Original language	English
Journal	Cardiovascular Diabetology
Volume	25
Issue number	1
Early online date	13 Mar 2026
DOIs	https://doi.org/10.1186/s12933-026-03097-0 https://doi.org/10.1186/s12933-026-03097-0
Publication status	Published - 13 Mar 2026
Externally published	Yes

Keywords

Cardiovascular function
Cohort profile
Diabetes mellitus
Energy metabolism
Glucose tolerance
Insulin sensitivity
Magnetic resonance imaging
Magnetic resonance spectroscopy
Myocardial infarction
Steatotic liver disease

Access to Document

Cite this

Möser, C., Prystupa, K., Schön, M., Yurchenko, I., Bódis, K. B., Huttasch, M., Michelotti, F., Kupriyanova, Y., Schrauwen-Hinderling, V., Granata, C., Bönhof, G. J., Strom, A., Herder, C., Dörr, D., Trenkamp, S., Heilmann, G., Bobrov, P., Straßburger, K., Szendroedi, J., ... Zaharia, O.-P. (2026). Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study. Cardiovascular Diabetology, 25(1). https://doi.org/10.1186/s12933-026-03097-0, https://doi.org/10.1186/s12933-026-03097-0

@article{363e3fb2d74145bebc923ba4d2ae81ad,

title = "Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study",

abstract = "BACKGROUND: Humans with type 2 diabetes and/or metabolic dysfunction-associated steatotic liver disease (MASLD) are at higher risk of ST-segment elevation myocardial infarction (STEMI) and worse prognosis. However, mechanisms, prognostic factors and risk subtypes in humans with STEMI and (pre)diabetes with or without MASLD, are not fully understood.METHODS: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) study is a prospective longitudinal cohort study, recruiting humans with different degrees of glucose tolerance after recent STEMI. This cohort study has the primary objective to detect changes in glycemia and insulin sensitivity derived from the oral glucose tolerance test (OGTT) and their relationships to cardiac function. Secondary objectives address tissue-specific insulin sensitivity and organ function, focusing on adipose tissue, liver and heart. Exploratory objectives comprise multiomic analyses and measures of mitochondrial function and quality of life. At 2 and 12 months after STEMI, participants undergo comprehensive cardiometabolic phenotyping (OGTT, modified Botnia clamp-test, magnetic resonance imaging/spectroscopy/elastography, high-resolution respirometry). Magnetic resonance-based techniques are employed to assess cardiovascular function and structure, adipose tissue distribution, skeletal muscle and hepatic lipid deposition and fibrosis, and hepatic energy metabolism. Exploratory analyses include multiomics of blood, urine, and stool samples. Multiomics analyses shall allow detecting biomarkers for stratification of cardiovascular disease risk. Currently, 100 participants have been included in DISTEMI, of whom 29\% have type 2 diabetes.CONCLUSION: The DISTEMI study integrates comprehensive cardiometabolic phenomic with multiomic profiling to identify cardiometabolic STEMI subtypes and predictors of outcomes, and to improve precision risk stratification and targeted prevention.TRIAL REGISTRATION: NCT05046483.",

keywords = "Cardiovascular function, Cohort profile, Diabetes mellitus, Energy metabolism, Glucose tolerance, Insulin sensitivity, Magnetic resonance imaging, Magnetic resonance spectroscopy, Myocardial infarction, Steatotic liver disease",

author = "Clara M{\"o}ser and Katsiaryna Prystupa and Martin Sch{\"o}n and Iryna Yurchenko and B{\'o}dis, \{K{\'a}lm{\'a}n B\} and Maximilian Huttasch and Filippo Michelotti and Yuliya Kupriyanova and Vera Schrauwen-Hinderling and Cesare Granata and B{\"o}nhof, \{Gidon J\} and Alexander Strom and Christian Herder and Daniel D{\"o}rr and Sandra Trenkamp and Geronimo Heilmann and Pavel Bobrov and Klaus Stra{\ss}burger and Julia Szendroedi and Mareike Cramer and Amin Polzin and Christian Jung and Malte Kelm and Volker Burkart and Robert Wagner and Michael Roden and Oana-Patricia Zaharia",

note = "Publisher Copyright: {\textcopyright} 2026. The Author(s).",

year = "2026",

month = mar,

day = "13",

doi = "10.1186/s12933-026-03097-0",

language = "English",

volume = "25",

journal = "Cardiovascular Diabetology",

issn = "1475-2840",

publisher = "BioMed Central Ltd.",

number = "1",

}

Möser, C, Prystupa, K, Schön, M, Yurchenko, I, Bódis, KB, Huttasch, M, Michelotti, F, Kupriyanova, Y, Schrauwen-Hinderling, V, Granata, C, Bönhof, GJ, Strom, A, Herder, C, Dörr, D, Trenkamp, S, Heilmann, G, Bobrov, P, Straßburger, K, Szendroedi, J, Cramer, M, Polzin, A, Jung, C, Kelm, M, Burkart, V, Wagner, R, Roden, M & Zaharia, O-P 2026, 'Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study', Cardiovascular Diabetology, vol. 25, no. 1. https://doi.org/10.1186/s12933-026-03097-0, https://doi.org/10.1186/s12933-026-03097-0

TY - JOUR

T1 - Cohort profile

T2 - The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study

AU - Möser, Clara

AU - Prystupa, Katsiaryna

AU - Schön, Martin

AU - Yurchenko, Iryna

AU - Bódis, Kálmán B

AU - Huttasch, Maximilian

AU - Michelotti, Filippo

AU - Kupriyanova, Yuliya

AU - Schrauwen-Hinderling, Vera

AU - Granata, Cesare

AU - Bönhof, Gidon J

AU - Strom, Alexander

AU - Herder, Christian

AU - Dörr, Daniel

AU - Trenkamp, Sandra

AU - Heilmann, Geronimo

AU - Bobrov, Pavel

AU - Straßburger, Klaus

AU - Szendroedi, Julia

AU - Cramer, Mareike

AU - Polzin, Amin

AU - Jung, Christian

AU - Kelm, Malte

AU - Burkart, Volker

AU - Wagner, Robert

AU - Roden, Michael

AU - Zaharia, Oana-Patricia

PY - 2026/3/13

Y1 - 2026/3/13

N2 - BACKGROUND: Humans with type 2 diabetes and/or metabolic dysfunction-associated steatotic liver disease (MASLD) are at higher risk of ST-segment elevation myocardial infarction (STEMI) and worse prognosis. However, mechanisms, prognostic factors and risk subtypes in humans with STEMI and (pre)diabetes with or without MASLD, are not fully understood.METHODS: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) study is a prospective longitudinal cohort study, recruiting humans with different degrees of glucose tolerance after recent STEMI. This cohort study has the primary objective to detect changes in glycemia and insulin sensitivity derived from the oral glucose tolerance test (OGTT) and their relationships to cardiac function. Secondary objectives address tissue-specific insulin sensitivity and organ function, focusing on adipose tissue, liver and heart. Exploratory objectives comprise multiomic analyses and measures of mitochondrial function and quality of life. At 2 and 12 months after STEMI, participants undergo comprehensive cardiometabolic phenotyping (OGTT, modified Botnia clamp-test, magnetic resonance imaging/spectroscopy/elastography, high-resolution respirometry). Magnetic resonance-based techniques are employed to assess cardiovascular function and structure, adipose tissue distribution, skeletal muscle and hepatic lipid deposition and fibrosis, and hepatic energy metabolism. Exploratory analyses include multiomics of blood, urine, and stool samples. Multiomics analyses shall allow detecting biomarkers for stratification of cardiovascular disease risk. Currently, 100 participants have been included in DISTEMI, of whom 29% have type 2 diabetes.CONCLUSION: The DISTEMI study integrates comprehensive cardiometabolic phenomic with multiomic profiling to identify cardiometabolic STEMI subtypes and predictors of outcomes, and to improve precision risk stratification and targeted prevention.TRIAL REGISTRATION: NCT05046483.

AB - BACKGROUND: Humans with type 2 diabetes and/or metabolic dysfunction-associated steatotic liver disease (MASLD) are at higher risk of ST-segment elevation myocardial infarction (STEMI) and worse prognosis. However, mechanisms, prognostic factors and risk subtypes in humans with STEMI and (pre)diabetes with or without MASLD, are not fully understood.METHODS: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) study is a prospective longitudinal cohort study, recruiting humans with different degrees of glucose tolerance after recent STEMI. This cohort study has the primary objective to detect changes in glycemia and insulin sensitivity derived from the oral glucose tolerance test (OGTT) and their relationships to cardiac function. Secondary objectives address tissue-specific insulin sensitivity and organ function, focusing on adipose tissue, liver and heart. Exploratory objectives comprise multiomic analyses and measures of mitochondrial function and quality of life. At 2 and 12 months after STEMI, participants undergo comprehensive cardiometabolic phenotyping (OGTT, modified Botnia clamp-test, magnetic resonance imaging/spectroscopy/elastography, high-resolution respirometry). Magnetic resonance-based techniques are employed to assess cardiovascular function and structure, adipose tissue distribution, skeletal muscle and hepatic lipid deposition and fibrosis, and hepatic energy metabolism. Exploratory analyses include multiomics of blood, urine, and stool samples. Multiomics analyses shall allow detecting biomarkers for stratification of cardiovascular disease risk. Currently, 100 participants have been included in DISTEMI, of whom 29% have type 2 diabetes.CONCLUSION: The DISTEMI study integrates comprehensive cardiometabolic phenomic with multiomic profiling to identify cardiometabolic STEMI subtypes and predictors of outcomes, and to improve precision risk stratification and targeted prevention.TRIAL REGISTRATION: NCT05046483.

KW - Cardiovascular function

KW - Cohort profile

KW - Diabetes mellitus

KW - Energy metabolism

KW - Glucose tolerance

KW - Insulin sensitivity

KW - Magnetic resonance imaging

KW - Magnetic resonance spectroscopy

KW - Myocardial infarction

KW - Steatotic liver disease

UR - https://www.scopus.com/pages/publications/105034455273

U2 - 10.1186/s12933-026-03097-0

DO - 10.1186/s12933-026-03097-0

M3 - Article

C2 - 41821026

SN - 1475-2840

VL - 25

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

IS - 1

ER -

Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this